Diagnostic Effectiveness of PCR-based Tests Detecting BRAF Mutation for Treating Malignant Melanoma: A Systematic Review

eISSN 2093-6338 Raf Kinase (BRAF) 유전자는 세포의 성장과 분화, 악성에 관여하 는 RAS/RAF/MEK/ERK 신호경로의 중요한 인자로서 흑색종, 대장 암, 갑상선암 등 다양한 종류의 종양 발생과 관련이 있다[1]. 미국 National Comprehensive Cancer Network (NCCN) [2]에서 는 미국 FDA 및 Clinical Laboratory Improvement Amendments (CLIA)에서 인증하는 검사실에서 BRAF V600E 유전자 돌연변이 가 확인된 경우 vemurafenib 치료를 권고하고 있다. 영국 National Health Service (NHS)의 의료기술평가 기관인 National Institute for Health and Clinical Excellence (NICE) [3]에서 2012년 보고한 권고지침에 따르면 vemurafenib은 적출이 불가능하거나 전이된

[1]  M. Silverstein,et al.  DCIS Treated with Excision Alone Using the National Comprehensive Cancer Network (NCCN) Guidelines , 2013, Annals of Surgical Oncology.

[2]  S. Kweon,et al.  BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. , 2013, The Journal of investigative dermatology.

[3]  F. López-Ríos,et al.  Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib , 2013, PloS one.

[4]  H. Moch,et al.  Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques , 2012, Case Reports in Oncology.

[5]  H. Kwon,et al.  Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas , 2012, Korean journal of pathology.

[6]  Suzanne Cheng,et al.  Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[7]  James Ziai,et al.  BRAF mutation testing in clinical practice , 2012, Expert review of molecular diagnostics.

[8]  K. Bloom,et al.  Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. , 2012, Archives of pathology & laboratory medicine.

[9]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[10]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[11]  M. Gu,et al.  Automated Silver-enhanced In Situ Hybridization for Evaluation of HER2 Gene Status in Breast Carcinoma: Comparison with Fluorescence In Situ Hybridization and Immunohistochemistry , 2010 .

[12]  R. Ádány,et al.  Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma , 2009, Modern Pathology.

[13]  C. Petti,et al.  In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation , 2008, Modern Pathology.

[14]  Young Kun Kim,et al.  The Relationship between the BRAF Mutations in Thyroid Papillary Carcinomas and the Prognostic Factors , 2005 .

[15]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[16]  V. Hentz,et al.  Contractures of the Hand , 2004 .

[17]  김진오,et al.  악성 흑색종에 대한 임상적 고찰 , 1997 .

[18]  V. McGovern.  The nature of melanoma. A critical review , 1982, Journal of cutaneous pathology.

[19]  N. Hayward,et al.  The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. , 2010, The Journal of investigative dermatology.

[20]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.